TABLE 4.
List of selected target gene variations, variant allele fractions (VAF), and recommendations from MDTS‐PM
| Gene | Variation | VAF (%) | Recommended drug |
|---|---|---|---|
| EGFR | L858R | 24.35 | Gefitinib, erlotinib, icotinib, afatinib, dacomitinib, osimertinib |
| PIK3CA | H1047R | 24.14 | Everolimus, tansimus, copanlisib |
| ERBB2 | S310F | 14.47 | TDM‐1 |
| RB1 | E837 | 15.22 | – |
| TMB<100 | Low TMB | – | – |
Abbreviations: ERBB2, Erb‐b2 receptor tyrosine kinase 2; EGFR, epidermal growth factor receptor; PIK3CA, phosphatidylinositol 3‐kinase catalytic alpha polypeptide gene; RB1, retinoblastoma gene1; TMB, tumor mutation burden.